Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Core identity/ingredient, indication, and mechanism are consistent with the supplied label excerpts. Several efficacy/wording claims are only partially supported due to non-verbatim phrasing. Two adverse-effect statements are marked as absent from label without supporting absence evidence from the provided label text, reducing audit confidence.
Category Scores
Accurate Statements
Rhofade is a prescription topical cream.
2 DOSAGE AND ADMINISTRATION; 1 INDICATIONS AND USAGE
Rhofade contains oxymetazoline.
11 DESCRIPTION
Rhofade is used to treat facial redness associated with rosacea.
1 INDICATIONS AND USAGE
Rhofade treats erythematous skin associated with rosacea (facial erythema).
1 INDICATIONS AND USAGE (facial erythema associated with rosacea in adults)
Oxymetazoline in Rhofade is a vasoconstrictor.
12 CLINICAL PHARMACOLOGY (12.1 Mechanism of Action)
Unsupported Statements
Application details for Rhofade can vary by prescription and product instructions.
No supporting label text was provided in the supplied excerpts addressing variability by prescription/product instructions.
Topical vasoconstrictor creams for rosacea can have skin irritation as a side effect at the application site.
The adverse reactions section content was not provided in the supplied label excerpts; therefore support/absence cannot be verified from the provided text.
Topical vasoconstrictor creams for rosacea can have redness at the application site as a side effect.
The adverse reactions section content was not provided in the supplied label excerpts; therefore support/absence cannot be verified from the provided text.
Contradictions
Low
AI Statement
Topical vasoconstrictor creams for rosacea can have skin irritation and redness at the application site as side effects.
Label Reference
6 ADVERSE REACTIONS (not provided in supplied excerpts)
Important Omissions
No specific FDA label administration instructions were included in the provided claim list (e.g., apply pea-sized amount once daily in thin layer to cover entire face; avoid eyes/lips; wash hands; priming for pump formulations).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unverified adverse-effect claims and insufficiently supported statements about side effects create audit uncertainty. Efficacy/mechanism wording is largely consistent, but omission of specific dosing/application directions could lead to misinterpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Adverse-effect statements (irritation/redness at application site) and variability-of-application statement are not verifiable from the provided label excerpts; determinations of 'absent from label' are unsupported without the adverse reactions text.
Suggested Improvement
Restrict claims to label-supported text from the provided excerpts (Indications, Description, Mechanism of Action, and Dosage/Administration). For adverse reactions, cite the exact language from the label’s 'Adverse Reactions' section; otherwise omit.